RxDoctor Payments Data

Ajith Ramachandran, MD

Internal Medicine · Greensboro, NCNPI 1235125170

Payments from drug & device makers

$16,799in general payments, 2019–2025

Across 1,127 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$3K
  • UCB, Inc.$2K
  • GSK$1K
  • Novartis$941
  • Boehringer Ingelheim$814
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$250%
  • Food & beverage$16,62099%
  • Education$951%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)223$2,607
AbbVie156$2,519
UCB, Inc.111$1,779
GSK80$1,193
Novartis51$941
Boehringer Ingelheim49$814
Mallinckrodt Hospital Products Inc.43$788
Johnson & Johnson(2 entities)39$625
Lilly USA, LLC48$594
AstraZeneca16$383
Novo Nordisk37$378
Mannkind Corporation34$352
Bayer26$350
Sanofi-aventis U.S. LLC22$317
Astellas Pharma US Inc17$267
Daiichi Sankyo Inc.11$206
Sumitomo Pharma America, Inc.10$196
Organon11$192
Amarin Pharma, Inc.12$166
Esperion Therapeutics, Inc.10$161
Pfizer10$149
Eisai Inc.10$129
Radius Health, Inc.6$119
Sandoz6$117
Otsuka America Pharmaceutical, Inc.6$98
Biohaven Pharmaceutical Holding Company Ltd.5$97
Merck7$95
E.r. Squibb & Sons, L.L.C.6$80
Fresenius Kabi USA, LLC3$79
Biohaven Pharmaceuticals, Inc.4$77
Xeris Pharmaceuticals, Inc.5$75
ANI Pharmaceuticals, Inc.4$61
Kowa Pharmaceuticals America, Inc.5$60
Mallinckrodt Enterprises LLC3$59
Medtronic2$44
Sanofi Pasteur Inc.2$40
Currax Pharmaceuticals LLC3$39
Teva Pharmaceuticals USA, Inc.3$38
Idorsia Pharmaceuticals US Inc2$34
Lifescan, Inc.2$32
Dexcom, Inc.2$31
Pharmacosmos Therapeutics Inc.2$30
Shield Therapeutics Inc2$28
Aurinia Pharma U.S., Inc.1$25
Kiniksa Pharmaceuticals International, PLC1$24
Takeda Pharmaceuticals U.S.A., Inc.2$23
Kiniksa Pharmaceuticals, Ltd.1$23
IBSA Pharma Inc.1$23
Seqirus USA Inc1$21
Sunovion Pharmaceuticals Inc.1$21
Philips North America LLC1$21
Ultragenyx Pharmaceutical Inc.1$19
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$17
Portola Pharmaceuticals, LLC1$17
CSL Behring1$17
Irhythm Technologies, Inc.1$15
Medicomp Inc1$15
Abbott1$15
Inspire Medical Systems, Inc.1$14
Mylan Specialty L.p.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,799 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$108,699
Medicare patients
187
Services billed
1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$98,647
EliquisApixaban148$92,971
OzempicSemaglutide64$77,448
XareltoRivaroxaban81$65,448
FarxigaDapagliflozin Propanediol113$61,161
MounjaroTirzepatide50$58,172
JanuviaSitagliptin Phosphate35$44,622
TrulicityDulaglutide20$33,807
Repatha SureclickEvolocumab32$22,766
Tresiba Flextouch U-200Insulin Degludec18$18,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,546
MyrbetriqMirabegron13$15,380
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,274
ShingrixVaricella-Zoster Ge/As01b/Pf47$10,476
JanumetSitagliptin Phos/Metformin Hcl16$7,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$814$104,728119 claims
PfizerEliquis, Paxlovid$149$97,182175 claims
Lilly USA, LLCMounjaro, Trulicity$594$91,97870 claims
Novo NordiskOzempic$378$77,44864 claims
AstraZenecaFarxiga, Breztri Aerosphere$383$74,435134 claims
Johnson & JohnsonXarelto$625$65,44881 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$95$59,18466 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$1,193$36,414101 claims
Astellas Pharma US IncMyrbetriq$267$15,38013 claims
AbbVieSynthroid$2,519$5,74874 claims
Esperion Therapeutics, Inc.Nexletol$161$5,54612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →